Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody
Author: ["Robert M Sharkey","Thomas M Cardillo","Edmund A Rossi","Chien-Hsing Chang","Habibe Karacay","William J McBride","Hans J Hansen","Ivan D Horak","David M Goldenberg"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Here we describe molecular imaging of cancer using signal amplification of a radiotracer in situ by pretargeting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), which subsequently also captures a radioactive hapten-peptide. Human colon cancer xenografts as small as ∼0.15 g were disclosed in nude mice within 1 h of giving the radiotracer, with tumor/blood ratios increased by ≥40-fold (∼10:1 at 1 h, ∼100:1 at 24 h), compared to a 99mTc-labeled CEA-specific F(ab′) used clinically for colorectal cancer detection, while also increasing tumor uptake tenfold (∼20% injected dose/g) under optimal conditions. This technology could be adapted to other antibodies and imaging modalities.
Cite this article
Sharkey, R., Cardillo, T., Rossi, E. et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11, 1250–1255 (2005). https://doi.org/10.1038/nm1322
